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Abstract
Tubulocystic renal carcinoma is a recently described neoplasm of low grade malignancy which was not
included in the last WHO 2004 classification. The tumor is extremely rare with less than one hundred casesRenal cells reported to date. In this article, the literature about that rare renal neoplasm is reviewed and an additional
case is reported.
© 2012 Production and hosting by Elsevier B.V. on behalf of Pan African Urological Surgeons’ Association.
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Tubulocystic renal carcinoma (TCRC) is a recently described neo-
plasm which was not included in the last WHO 2004 classification
[1]. It consists of a mixture of tubules and micro/macro cysts with
low-grade nuclear features and appears to derive from proximal
convoluted tubule and distal nephron. The mean age is 54 years and
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CC BY-NC-ND license.5% of patients are male [2]. Prognosis is usually excellent with
nly rare distant metastases or death from disease. The tumor is
xtremely rare with less than one hundred cases reported to date
3]. Herein, we review the literature about that rare renal neoplasm
ollowed by report of an additional case.
iterature  review
idney cancer is among the ten most common causes of cancer-
elated death in adults [4]. Over 64,700 new cases and over 13,500
eaths are expected to occur in the US in 2012 [5]. Renal cell
arcinoma (RCC) constitutes more than 80% of all primary renal
eoplasms, and clear cell RCC (ccRCC) accounts for most of these
ases (80%). Updates to the histopathological diagnosis of kidney
eoplasms were last reflected in the latest World Health Organiza-
ion (WHO) classification of genitourinary and kidney neoplasms
ense.ntroduced in 2004 [1]. Ongoing research since then has led, how-
ver, to the description of new tumor entities. One of these is the
xtremely rare tubulocystic renal carcinoma of which less than
ne hundred cases have been reported to date [3]. TCRC was not
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ncluded in the WHO 2004 classification. However, the very recent
010 AJCC/UICC TNM, 7th edition, cancer protocol for RCC now
ecognizes this tumor as a distinct entity [6].
linically, TCRCs occur predominantly in men with a wide age
ange and a mean of 54 years [2]. They are less aggressive than
ther renal carcinomas. Most present when small (pT1); and only
arely progress, recur, or metastasize [3,7–9]. In the vast majority of
eports, TCRC has been an incidental finding on autopsy, nephrec-
omy for a separate disease process, or imaging [6]. Other clinical
resentations included abdominal distention, pain, hematuria or a
enal mass [3,10,11].
CRC was originally thought to be a subtype of collecting duct
arcinoma (CDC) that was first described by Masson who named
t “Bellinian epithelioma” or “carcinoma of the collecting ducts” as
e believed it originated from collecting ducts of Bellini [12]. Col-
ecting duct carcinoma is an uncommon variant of RCC that has been
roven to be highly aggressive and associated with poor prognosis
13]. Beginning in the mid-90s, there were reports of a potentially
ow-grade variant of CDC that had a distinctively benign course.
acLennan et al. in 1997 hypothesized that this tumor represented
he low grade of the spectrum of collecting duct carcinoma, as it
hares similar characteristics with the latter tumor [14]. In 2004,
min et al. named the tumor “tubulocystic carcinoma” in a series
f 29 cases [15]. A recent study by Osunkoya et al. has shown that
CRC is distinct from CDC at the molecular level [16].
istologically, TCRC is a well-circumscribed neoplasm consisting
f cysts and tubules lined by mildly atypical cells with abundant
osinophilic cytoplasm, prominent nucleoli and a variable hobnail
ppearance. Grossly, these tumors frequently display a cystic com-
onent which renders a radiological classification of Bosniak III
r IV [3]. The Bosniak classification system for CT evaluation
f renal cysts, introduced in 1986, has been used to help evaluate
he malignant risk of cystic renal masses and decide their clinical
anagement [17]. Category I lesions are benign simple cysts with
airline-thin walls. These cysts contain no septa, calcifications, or
olid components and do not show enhancement after intravenous
ontrast material administration. Category II masses are benign
ystic lesions that may contain hairline-thin septa. Fine calcifica-
ion in the walls or septa of such lesions, or a short segment of
lightly thickened calcification, may be present. Minimal perceived
not measurable) enhancement of a hairline-thin smooth septum or
all is sometimes present. Lesions with uniformly high attenuation
high-attenuation cysts) that are less than 3 cm in diameter and do
ot enhance are included in this category. Category IIF (the “F”
ndicates need for follow-up imaging) lesions are more complex
ysts that cannot be neatly classified as category II or III lesions.
hese cysts may contain an increased number of hairline-thin septa
r have minimal but smooth thickening of the wall or septa. The
all and/or septa may contain calcifications, which may be thick
nd nodular, without obvious enhancement. Like category II cysts,
hese lesions may demonstrate minimal perceived enhancement of a
airline-thin smooth septum or wall; however, there are no enhanc-
ng soft-tissue components. Nonenhancing high-attenuation lesions
high-attenuation cysts) that are completely intrarenal and are 3 cm
r larger are also included in this category. Category III lesions
re indeterminate masses, and it usually cannot be determined at
maging whether they are benign or malignant. They have thickened
rregular walls or septa, in which enhancement can be demonstrated.
ategory IV lesions are malignant cystic masses. They may have
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ndings similar to those seen in Category III masses but also have
nhancing soft-tissue components adjacent to, but independent of,
he wall or septum.
he relationship of TCRC to collecting duct (Bellini duct) car-
inoma remains controversial. As mentioned previously, TCRC
as considered in the past, to be a tumor of collecting duct ori-
in and was sometimes confused with collecting duct carcinoma,
n aggressive infiltrative solid tumor with poor prognosis. There-
ore, an “evolving concept” of collecting duct carcinomas was
roposed, and low-grade collecting duct carcinoma at the beginning
f the spectrum corresponded to the current TCRC [14]. However,
mmunohistochemical and ultrastructural studies demonstrated the
oor relationship between TCRC and collecting duct tumors [18].
hese tumors show expression of proteins of proximal convoluted
ubules (CD10 and P504S), distal tubules (CK19) and intercalated
ollecting duct cells (parvalbumin). They also show vimentin, p53
nd alpha methylacyl CoA racemase (AMACR) over-expression
n contrast to CDC [16]. Ultrastructurally, they display abundant
icrovilli with brush border organization as proximal convoluted
ubule cells, but with short microvilli and cytoplasmic interdigita-
ion, similar to intercalated cells of the collecting duct [18]. Those
bservations led to the conclusion that TCRC shows aberrant renal
ubular differentiation rather than originating from collecting ducts.
ang et al. demonstrated a unique molecular signature of tubulo-
ystic carcinoma in comparison to other renal tumors and normal
enal tissue using gene expression microarray analysis. Clustering
nalysis of that data revealed tubulocystic carcinoma to be closely
elated to papillary RCC; both types 1 and 2 dimensional clustering
laced tubulocystic carcinoma between low and high grade papillary
CC. Comparative genomic microarray analysis was performed and
emonstrated gains of chromosome 17p and 17q (trisomy 17), sim-
lar to papillary RCC. Gains of chromosome 7p and 7q (trisomy 7),
lso characteristic of papillary RCC, were not identified in the one
ase of tubulocystic carcinoma studied [8].
here are sporadic reports about the coexistence of TCRC with other
enal tumors of different subtypes. Yang et al. reported 5 cases of
CRC associated with either papillary RCC or papillary adenomas
8]. Gonul et al. reported a case of synchronous clear cell RCC,
icropapillary urothelial carcinoma and TCRC in a 57-year-old
ale with hematuria [19]. Brennan et al. presented a case of a 72-
ear-old male with end stage renal disease who developed a TCRC,
 type 2 papillary RCC, a clear cell papillary and cystic RCC as well
s renal oncocytosis, hybrid tumors and chromophobe RCC [20].
ore recently, Deshmukh et al. reported a synchronous TCRC and
apillary RCC in a young female with metastatic papillary RCC
n para-aortic lymph nodes [21]. Thus, although TCRC has been
eported in association with multiple other renal cell tumor subtypes,
t appears that there is a slight predominance for synchronous TCRC
nd papillary tumors. An interesting question raised by the coexis-
ence of TCRC with other renal tumors is whether there are common
redisposing factors for these histologically different tumors.
he differential diagnosis of TCRC includes collecting duct carci-
oma and other cystic renal tumors, mainly, cystic nephroma, low
rade multilocular cystic renal cell carcinoma and mixed epithe-
ial and stromal tumor of the kidney. Moreover, some chromophobe
arcinomas and some oncocytomas may be entirely cystic. Non-
eoplastic renal cysts and tumors commonly associated with renal
ystic diseases have also to be considered.
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Table  1  Clinical and radiological findings in present case as compared to 10 recently reported cases.
Author Number of cases Age (years) Sex Clinical
presentation
Stage at diagnosis CT
Present study (2012) 1 38 Male Recurrent flank
pain, renal mass
II Bosniak III
Moses et al. (2010) [6] 1 68 Male Incidental I Bosniak I
Horra et al. (2011) [3] 5 29–70 (mean 54) Male Renal mass I (3 cases)
IV (2 cases)
Bosniak III (2 cases)
Bosniak IV (1 case)
Solid (1 case)
Bhullar et al. (2011) [10] 1 33 Male Back pain, renal
mass
IV Bosniak IV
Deshmukh et al. (2011) [21] 1 18 Female Hematuria, renal
mass
II Bosniak IV
Male Incidental I Solid
Figure  1  Tubulocystic carcinoma. CT urography showing well
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RQuiroga-Garza (2012) [11] 1 67 
Collecting duct carcinoma can be ruled out by its solid rather than
cystic nature as well as its high grade nuclear features [13]. Immuno-
histochemical findings may also help in the differential diagnosis
[16,18].
Cystic nephroma occurs in children under the age of 2 years old and
women 40–69 years old. The architecture is cystic and contains
no tubules and the cysts are lined by flattened cells with indis-
tinct nucleoli. Of interest, cystic nephroma shows a striking female
predominance (8:1), whereas TCRC occurs more often in men [7].
Low-grade multilocular cystic renal cell carcinoma was described in
the WHO 2004 classification as a new entity, accounting for approx-
imately 4% of cc RCCs [1]. It affects middle aged women with a
male to female ratio of 1.2:2.1. Up to 90% of cases are discovered
incidentally on radiologic investigation for other causes [22]. The
tumor is a variant of clear cell carcinoma displaying large cysts lined
by clear cells, separated by fibrous septa containing nests of clear
cells [23].
The mixed epithelial and stromal tumor is a multicystic or biphasic
tumor with solid and cystic areas. In the adult population, it shows a
marked female preponderance like cystic nephroma to which it may
be closely related [22]. Steroid hormones have been suggested to
play a role in the genesis and evolution of this tumor; women with
these tumors often have a history of long-term estrogen replace-
ment, whereas many men with the tumor have had long-term sex
steroid exposure. Estrogen receptors and progesterone receptors are
frequently expressed in the mesenchymal component and the stroma
may be of ovarian type [24].
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Figure  2  Tubulocystic carcinoma, gross. Note multilocular cystic appearaefined, multiloculated cystic mass in the left kidney with thick enhanc-
ng septations and small mural nodules in keeping with category III
osniak classification.
n cystic chromophobe carcinomas and oncocytomas, the cysts are
ined by chromophobe cells or oncocytic cells, respectively. In the
atter, oncocytic cells are usually cuboidal with round central nuclei
nd are classically CD10 and CK7 negative by immunochemistry
7].
eport  of  a  case 38 years old Sudanese male presented with recurrent episodes
f left flank pain of 8-month duration. No other relevant symptoms
ere present. On clinical examination, a firm right renal swelling
nce of excised tumor (left) and in tumor bed in center of kidney (right).
4 I. Khalaf et al.
Figure  3  Tubulocystic carcinoma. H&E stained sections showing tubules and cysts (100×), and “hobnail cells”, some showing prominent nucleoli
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s400×, lower right).
as palpable. Past history was irrelevant. Family history was posi-
ive for renal cancer in the patient’s uncle. Laboratory investigations
howed normal hematologic, renal and hepatic data.
T urography revealed a 15 cm ×  13 cm well defined, multilocu-
ated cystic mass in the left kidney with thick enhancing septations
nd small mural nodules in keeping with category III Bosniak
lassification, compressing and displacing the calyces with mild
elvicalyceal system dilatation (Fig. 1).
here were no metastases at the time of surgery.
he clinical and radiological findings in our case as compared to 10
ecently reported cases are depicted in Table 1.
 left radical nephrectomy was performed and sent for pathologic
tudy.
he specimen received in the laboratory consisted of a renal mass,
n opened left kidney and few separate small grayish tissue frag-
ents. The renal mass appeared grossly as an already opened large
ultilocular cystic mass, 15 cm ×  8 cm ×  3 cm (Fig. 2). The wallsf the cyst were firm, gray with nodular and hemorragic areas. The
idney measured 10 cm ×  7 cm ×  3 cm and showed the tumor bed
t its center. The small separate tissue fragments were firm, nodular
nd measured 6 cm ×  6 cm in aggregate.
C
t
Ticroscopic examination of 4 m thick, H&E-stained sections
rom the renal mass, the tumor bed in the kidney and the sepa-
ate tissue fragments revealed a neoplasm composed of irregular
ubules and variably sized cysts lined by cuboidal cells with
bundant eosinophilic cytoplasm, exhibiting variable, mostly mild
uclear pleomorphism with focally prominent nucleoli (Fig. 3).
itosis was only occasionally encountered. A fibrotic stroma
nd a “hobnail appearance” of neoplastic cells were focally
bserved. There was also focal tumoral necrosis, hemorrhage and
ononuclear inflammatory cell infiltration. The tumor did not
nvade the renal capsule, peri-renal fat, renal sinus or adjacent
enal parenchyma. There was no evidence of vascular invasion
nd no involvement of the renal vein, artery or renal pelvis or
alyces. The ureteric resection margin was clear. Immunohisto-
hemically, the neoplastic cells showed reactivity for CK18, CK19,
MA, CD10, high molecular weight cytokeratin 34betaE12, and
imentin but no reactivity for CK7 (Fig. 4). Immunoreactivity
or CD10; CK19; and EMA, CK 18 and vimentin is in keep-
ng with proximal convoluted tubular, distal tubular and collecting
uct differentiation, respectively. The final diagnosis was “Tubu-
ocystic carcinoma, nuclear grade 2, pathologic stage T2b, TNM
tage T2 N0 M0 (Group stage II)”. It was based on rather typical
T, gross, microscopic and immunohistochemical features of the
umor.
he patient is free of disease 6 months after the surgery.
Tubulocystic renal cell carcinoma 5
plasm
[
[
[
[
[
[
[Figure  4  Tubulocystic carcinoma, immunohistochemistry. Note cyto
(200×), (C) CK18 (200×) and (D) Vimentin (200×).
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